Ensor CM - Search Results

1

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.

Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF. Ascierto PA, et al. Among authors: ensor cm. J Clin Oncol. 2005 Oct 20;23(30):7660-8. doi: 10.1200/JCO.2005.02.0933. J Clin Oncol. 2005. PMID: 16234528 Clinical Trial.

2

Regression of hepatocellular cancer in a patient treated with arginine deiminase.

Curley SA, Bomalaski JS, Ensor CM, Holtsberg FW, Clark MA. Curley SA, et al. Among authors: ensor cm. Hepatogastroenterology. 2003 Sep-Oct;50(53):1214-6. Hepatogastroenterology. 2003. PMID: 14571701

3

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.

Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, Curley SA. Izzo F, et al. Among authors: ensor cm. J Clin Oncol. 2004 May 15;22(10):1815-22. doi: 10.1200/JCO.2004.11.120. J Clin Oncol. 2004. PMID: 15143074 Clinical Trial.

4

Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.

Izzo F, Montella M, Orlando AP, Nasti G, Beneduce G, Castello G, Cremona F, Ensor CM, Holtzberg FW, Bomalaski JS, Clark MA, Curley SA, Orlando R, Scordino F, Korba BE. Izzo F, et al. Among authors: ensor cm. J Gastroenterol Hepatol. 2007 Jan;22(1):86-91. doi: 10.1111/j.1440-1746.2006.04463.x. J Gastroenterol Hepatol. 2007. PMID: 17201887

5

Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties.

Holtsberg FW, Ensor CM, Steiner MR, Bomalaski JS, Clark MA. Holtsberg FW, et al. Among authors: ensor cm. J Control Release. 2002 Apr 23;80(1-3):259-71. doi: 10.1016/s0168-3659(02)00042-1. J Control Release. 2002. PMID: 11943403

6

Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor alpha and endotoxin.

Thomas JB, Holtsberg FW, Ensor CM, Bomalaski JS, Clark MA. Thomas JB, et al. Among authors: ensor cm. Biochem J. 2002 May 1;363(Pt 3):581-7. doi: 10.1042/0264-6021:3630581. Biochem J. 2002. PMID: 11964159 Free PMC article.

7

Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production.

Dillon BJ, Holtsberg FW, Ensor CM, Bomalaski JS, Clark MA. Dillon BJ, et al. Among authors: ensor cm. Med Sci Monit. 2002 Jul;8(7):BR248-53. Med Sci Monit. 2002. PMID: 12118186

8

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.

Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Ensor CM, et al. Cancer Res. 2002 Oct 1;62(19):5443-50. Cancer Res. 2002. PMID: 12359751

9

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation.

Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Dillon BJ, et al. Among authors: ensor cm. Cancer. 2004 Feb 15;100(4):826-33. doi: 10.1002/cncr.20057. Cancer. 2004. PMID: 14770441 Free article.

10

Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.

Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA. Bomalaski JS, et al. Among authors: ensor cm. J Rheumatol. 2002 Sep;29(9):1942-9. J Rheumatol. 2002. PMID: 12233890

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters